华法林的药物基因组学研究及其临床应用进展  

Research progress on pharmacogenetics of warfarin and clinical application

作　　者：刘嘉[1,2] 王连生[1,2] 

机构地区：[1]中南大学湘雅医院临床药理研究所 [2]中南大学临床药理研究所遗传药理学湖南省重点实验室

出　　处：《中国临床药理学与治疗学》2015年第6期687-693,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金项目(81072707);国家高技术研究发展计划(863)项目(2012AA02A518)

摘　　要：华法林是临床上使用最广泛的抗凝药,其治疗窗窄,剂量个体差异大,很容易出现出血等不良反应。遗传因素又是影响华法林稳定剂量及不良反应最重要因素,与药效学、药代学及药物转运相关的基因都能够影响华法林的治疗。本文综述这些基因的研究现状及其临床应用的进展,旨在全面了解遗传因素对华法林治疗的影响,为临床的个体化治疗提供参考。Warfarin is widely used as oral anticoagulant drug with narrow therapeutic window,wide variations in dose requirements and patients easily suffer from adverse event such as bleeding.Genetic factor can significantly influence on the stability of the warfarin dose and adverse events. The genes relate of pharmacokinetics,pharmacodynamics and drug transport all can influence on warfarin therapy. The article reviews the current research status of these genes and the progress of clinical application,aiming to comprehensive understanding of the genetic factors effect on warfarin therapy,Providing reference and guidance for personalized treatment.

关 键 词：华法林 抗凝 药物基因组学 个体化治疗 

分 类 号：R965.1[医药卫生—药理学]